G. Stella (Pavia (PV), Italy), D. Xhemalaj (Tirana, Albania), E. Zervas (Athens, Greece), T. Blum (Berlin, Germany)
LSC - 2018 - Tumor-derived granulocyte chemotactic protein 2 cooperates with neutrophil proteinase 3 to drive lung adenocarcinoma A. Lamort, S. A Weiß (stefanie.weiss@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum München, M. of the German Center for Lung Research (DZL),Munich), I. Lillis (ioannislilis@upatras.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), V. Armenis (vasilisarmenis91@gmail.com / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), K. A M Arendt (kristina.arendt@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum München, M. of the German Center for Lung Research (DZL),Munich), M. Pepe (mario.pepe@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum München, M. of the German Center for Lung Research (DZL),Munich), L. V Klotz (laura.klotz@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum München, M. of the German Center for Lung Research (DZL),Munich), A. Marazioti (amarazioti@upatras.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), M. Spella (giopanou@upatras.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), I. Giopanou (giopanou@upatras.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), G. Ntaliarda (ntaliarda@upatras.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), G. A Giotopoulou (giotopoulou.g@gmail.com / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), M. Lianou (pha2306@upnet.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), M. Oplopoiou (moplopoiou@gmail.com / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), K. Kauka (katerinakauka2@gmail.com / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,,Rio), D. Jenne (dieter.jenne@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum München, M. of the German Center for Lung Research (DZL),Munich), G. T Stathopoulos (stathopoulos@helmholtz-muenchen.de / Comprehensive Pneumology Center, H. Zentrum München, M. of the German Center for Lung Research (DZL),Munich)
| |
LSC - 2018 - Nuclear factor ??-signalling drives Malignant Pleural Mesothelioma I. Giopanou, D. Simoglou (dsimoglou@gmail.com / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,Patras), M. Lianou (marina_lianou@hotmail.com / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,Patras), G. T Stathopoulos (gstathop@upatras.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,Patras)
| |
Alteration patterns of tobacco carcinogens in lung adenocarcinoma reveal novel KRAS-addicted candidate oncogenes M. Pepe (Munich, Germany), F. Pelizza (Glascow, United Kingdom), A. Lamort (Munich, Germany), N. Kanellakis (Patras, Greece), G. Stathopoulos (Munich, Germany)
| |
Depletion of STAT6 suppresses lung cancer progression through regulating M2-macrophage polarization C. Fu (SH, China), S. Li (SH, China)
| |
Ghrelin does not influence cancer progression in a lung cancer cell line and mice with lung adenocarcinoma H. Tsubouchi (Miyazaki, Japan), A. Miura (Miyazaki, Japan), S. Yanagi (Miyazaki, Japan), M. Nakazato (Miyazaki, Japan)
| |
The influence of brown adipose tissue on the proliferation and chemosensitivity in non-small cell lung cancer cells A. Frille (Leipzig, Germany), H. Kuhn (Leipzig, Germany), T. Ebert (Leipzig, Germany), H. Seyfarth (Leipzig, Germany), H. Wirtz (Leipzig, Germany)
| |
The influence of non-small cell lung cancer cells on the expression of adipokines in brown adipose tissue A. Frille (Leipzig, Germany), H. Kuhn (Leipzig, Germany), T. Ebert (Leipzig, Germany), H. Seyfarth (Leipzig, Germany), H. Wirtz (Leipzig, Germany)
| |
Tissue factor induced tumor vascular infarction in lung cancer L. Schmidt (Muenster, Germany), C. Brand (Muenster, Germany), J. Stucke-Ring (Muenster, Germany), S. Harrach (Muenster, Germany), C. Schliemann (Muenster, Germany), A. Marra (Bremen, Germany), L. Hillejan (Ostercappeln, Germany), C. Mueller-Tidow (Heidelberg, Germany), G. Lenz (Muenster, Germany), E. Wardelmann (Muenster, Germany), R. Wiewrodt (Muenster, Germany), T. Muley (Heidelberg, Germany), E. Herpel (Heidelberg, Germany), M. Mohr (Muenster, Germany), D. Goerlich (Muenster, Germany), M. Kreuter (Heidelberg, Germany), M. Thomas (Heidelberg, Germany), C. Schwoeppe (Muenster, Germany), W. Hartmann (Muenster, Germany), W. Berdel (Muenster, Germany)
| |
Micro RNA-21 Targeting PI3K/PTEN/Akt signaling axis regulates multiple biological functions in human lung cancer Y. Zheng (Shanghai, China), D. Zhang (Shanghai, China)
| |
Specific lung cancer peptides selected by a subtractive 3D cell-phage display technology L. Maia (Uberlandia, Brazil), E. Vaz (Uberlandia, Brazil), A. Souza (Uberlandia, Brazil), R. Melo (Uberlandia, Brazil), T. Cunha (Uberlandia, Brazil), L. Goulart (Uberlandia, Brazil)
| |
Analyzing the role of proteasome activator 200 (PA200) in lung cancer V. Welk (Munich, Germany), T. Meul (Munich, Germany), C. Lukas (Munich, Germany), D. Bölükbas (Lund, Sweden), I. Koch (Gauting, Germany), M. Lindner (Gauting, Germany), S. Meiners (Munich, Germany)
| |
Generation of small molecules targeting hypoxia inducible factors Y. Saygideger (Adana, Turkey), D. Kahraman (Gaziantep, Turkey), S. I?lhan (Gaziantep, Turkey), T. Tok (Gaziantep, Turkey), E. Basaran (Gaziantep, Turkey), A. Iyidogan (Gaziantep, Turkey), A. Üren (Washington DC, United States of America), E. Emre (Gaziantep, Turkey), H. Bayram (Istanbul, Turkey)
| |
Modulation of tumor-microenvironmental factors and cancer growth in co-cultures of fresh human lung tissue and patient-derived cancer cells S. Konzok (Hannover, Germany), S. Dehmel (Hannover, Germany), C. Werno (Hannover, Germany), P. Braubach (Hannover, Germany), G. Warnecke (Hannover, Germany), P. Zardo (Hannover, Germany), D. Jonigk (Hannover, Germany), O. Pfennig (Hannover, Germany), H. Fieguth (Hannover, Germany), B. Polzer (Hannover, Germany), K. Weidele (Hannover, Germany), C. Klein (Regensburg, Germany), A. Braun (Hannover, Germany), K. Sewald (Hannover, Germany)
| |
Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer K. Syrigos (Athens, Greece), I. Kotteas (Athens, Greece), M. Paraskeva (Athens, Greece), I. Gkiozos (Athens, Greece), P. Boura (Athens, Greece), S. Tsagouli (Athens, Greece), D. Grapsa (Athens, Greece), A. Charpidou (Athens, Greece)
| |
Uncommon EGFR mutations of lung adenocarcinoma in one tertiary institution, Korea: clinical characteristics and treatment response to tyrosine kinase inhibitors J. Chang (Seoul, Republic of Korea), Y. Han (Seoul, Republic of Korea), Y. Ryu (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea)
| |
Blocking beta adrenergic signaling may be a target for overcoming EGFR TKI resistance. E. Heo (Seoul, Republic of Korea), M. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), D. Kim (Seoul, Republic of Korea), H. Chung (Seoul, Republic of Korea)
| |
The impact of ß-blockers in non–small cell lung cancer patients treated with Epidermal Growth Factor Receptor Kinase Inhibitors, Taiwan NHIRD database study. G. Fan (Taipei, Taiwan), C. Lin (Taoyuan, Taiwan)
| |
Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy> M. Hung (Puzi city, Taiwan), M. Chuang (Puzi city, Taiwan), Y. Tsai (Puzi city, Taiwan), Y. Yang (Puzi city, Taiwan)
| |
Association of antiPD1 immunotherapy with immunogenic cell death-inducing chemotherapy in a murine model of squamous cell lung cancer M. Jeanvoine (Rouen, France), F. Guisier (Rouen, France), P. Bohn (Rouen, France), L. Thiberville (Rouen, France), M. Salaun (Rouen, France)
| |
Immune Checkpoint Inhibitors-related Intersticial Lung Disease in patients with thoracic tumors: experience of one institution F. Ramalho Fernandes (Guarda, Portugal), T. Almodovar (Lisboa, Portugal), I. Duarte (Lisboa, Portugal), D. Costa (Lisboa, Portugal)
| |